SCHEDULE: Invesco Ltd. Reports 4.9% Stake in Collegium Pharma
Beneficial Ownership Disclosure
Invesco Ltd. has disclosed a 4.9% beneficial ownership stake in Collegium Pharmaceutical Inc. as a passive investor.
Summary
- Invesco Ltd. reported beneficial ownership of 1,584,871 shares of Collegium Pharmaceutical Inc. common stock.
- This represents 4.9% of the class of securities, falling below the 5% threshold for active reporting.
- Invesco Ltd. holds sole voting power over 1,460,375 shares and sole dispositive power over 1,584,871 shares.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a previous filing by Invesco Ltd. regarding its stake.
- Invesco Ltd. is classified as a parent holding company and investment adviser, and the shares are held by clients.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of passive beneficial ownership and does not contain information that would significantly alter the sentiment towards Collegium Pharmaceutical Inc. It is a neutral, compliance-driven update.
Positives
- Invesco Ltd., a major global investment manager, maintains a significant, albeit passive, stake in Collegium Pharmaceutical Inc., which could be viewed as a vote of confidence in the company's long-term prospects.
Future Outlook
This filing is a routine disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from Collegium Pharmaceutical Inc. or Invesco Ltd. regarding the issuer's future performance or strategic direction.
Industry Context
This filing reflects a routine passive investment by a large asset manager, Invesco Ltd., in a pharmaceutical company, Collegium Pharmaceutical Inc. It is a standard disclosure required when an institutional investor's beneficial ownership reaches certain thresholds, indicating ongoing portfolio management rather than a strategic industry move or competitive action.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake, confirming Invesco Ltd.'s continued investment in the company.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement |
| 08/07/2025 | Signature date of the filing by Robert R. Leveille, Global Head of Compliance for Invesco Ltd. |
Keywords
Collegium Pharmaceutical, Invesco Ltd., Schedule 13G, Beneficial Ownership, Common Stock, Pharmaceutical, Investment Management, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.